This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Depression Drugs Market

Market Insights on Depression Drugs covering sales outlook, demand forecast & up-to-date key trends

Depression Drugs Market: Global Industry Analysis and Opportunity Assessment 2022-2032

Depression Drugs Market Overview

The global depression drugs market was valued at around US$ 15.3 Bn at the end of 2021. The market is projected to register a 3.7% CAGR and top a valuation of US$ 22.0 Bn by 2032.

“The Rising prevalence of social anxiety and depression is expected to uplift the depression drugs market over the forecast period.”

Depression is a mental disorder defined by a lack of pleasant feelings, a chronically depressed mood, and a wide range of cognitive, physical, behavioral, and emotional symptoms. It is diagnosed by determining the symptoms and reviewing the patient's medical history. The condition is then treated with antidepressants, which stabilize neurotransmitters like serotonin that function in the brain and regulate the patient's mood and emotions. These medications can help to lessen the symptoms of dysthymia, seasonal affective disorder, and anxiety.

Attributes

Details

Depression Drugs Market Value in 2021

US$ 15.3 Bn

Depression Drugs Market Value in 2032

US$ 22.0 Bn

Depression Drugs Market CAGR (2022-2032)

3.7%

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Major Drivers Boosting the Demand for Depression Drugs Market?

Depression is a prevalent mental disorder. According to estimates, 5% of the populaiton worldwide experience depression. Depression is a major contributor to the overall global burden of disease, a primary cause of disability around the world, and it has an impact on the quality of life for those who are suffering from this condition. It is speculated that depression is more prevalent in women as compared to males. Over the forecast period, the market for depression drugs is anticipated to be driven by increased rates of social anxiety disorder, depression, and related illnesses.

The adoption rate is also rising as a result of the aging population, which is more vulnerable to certain medical problems. In the upcoming years, the depr4ession drugs market growth is predicted to be fueled by the development of novel therapies for the treatment of depression and the introduction of new antidepressants with negligible side effects and long-term outcomes.

The prevalence of mental health issues is rising, which is causing the market for treating depression to expand. These variables include demographic changes, environmental changes, mental stress, and more.

Which Region Shows Strong Growth Potential in the Depression Drugs Market?

The depression drugs market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.

North America is the leading region in the global depression drugs market owing to the increasing number of people suffering from depression and rising campaigns about mental health led by profitable and non-profitable organizations.

The European depression drugs market is also expected to display lucrative growth in the projected years due to a more aware and concerned populace regarding anxiety and depressive disorders.

The East Asian region is predicted to show lucrative growth owing to the growing knowledge amongst the general population about mental disorders and mental well-being.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Who are the Key Players in the Depression Drugs Market?

Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals.

Scope of Report

Report Attributes

Details

Growth Rate

CAGR of 3.7% 2022-2032

Base Year for Estimation

2021

Historical Data

2012-2021

Forecast Period

2022-2032

Qualitative Units

Revenue in USD Billion, and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends

Segment Covered

  • Disorder
  • Drug Class
  • Distribution Channel
  • Region

Region Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Players

  • Otsuka Pharmaceutical
  • Pfizer
  • Eli Lilly and Company
  • AstraZeneca
  • Novartis
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Takeda Pharmaceutical Company
  • Allergan
  • Johnson & Johnson
  • Zhejiang NHU Company Ltd
  • Sebela Pharmaceuticals

Customization

Available Upon Request

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Key Segments Covered in the Depression Drugs Market Report

By Disorder:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

By Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Serotonin Antagonist & Reuptake Inhibitors
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

The global depression drugs market is anticipated to register a CAGR of 3.7% during the forecast period.

The global depression drugs market is projected to be about US$ 22.0 Bn by the end of year 2032.

Table of Content

NA

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Depression Treatment Market

Published : May 2022

Healthcare

Drug Free Depression Treatment Market

Published : March 2019

Healthcare

Postpartum Depression Management Market

Published : September 2017

Google translate

Depression Drugs Market